Authors: | Heerdt, A. S.; Borgen, P. I. |
Article Title: | Current status of tamoxifen use: An update for the surgical oncologist |
Abstract: | The surgical oncologist is frequently responsible for the screening and diagnosis of women with breast cancer. In this pivotal role, they are often the first to discuss treatment options, including nonsurgical interventions, with breast cancer patients. Recent long-term clinical trial data provide support for the use of tamoxifen to prevent breast cancer in women at high risk of the disease. A breast cancer risk assessment can help identify women at higher than average risk for the disease, who may be appropriate candidates for chemoprevention. It is important for the surgical oncologist to understand the current indications and evidence regarding the use of tamoxifen for breast cancer prevention and treatment as they counsel their patients on available options. |
Keywords: | cancer survival; review; cancer risk; combined modality therapy; endometrium carcinoma; chemoprophylaxis; breast neoplasms; high risk patient; risk assessment; lung embolism; cancer inhibition; drug mechanism; randomized controlled trials; breast carcinoma; tamoxifen; antineoplastic agents, hormonal; estrogen receptor; patient counseling; clinical trials; mastectomy, segmental; chemoprevention; estrogen antagonists; humans; human; female; priority journal; antiestrogens |
Journal Title: | Journal of Surgical Oncology |
Volume: | 72 |
Issue: | 1 |
ISSN: | 0022-4790 |
Publisher: | Wiley Blackwell |
Date Published: | 1999-09-01 |
Start Page: | 42 |
End Page: | 49 |
Language: | English |
DOI: | 10.1002/(sici)1096-9098(199909)72:1<42::aid-jso13>3.0.co;2-e |
PUBMED: | 10477879 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | Review -- Export Date: 16 August 2016 -- Source: Scopus |